T cells are the immune system’s frontline fighters. When they detect danger, they rapidly multiply and transform into ...

The deal gives Cullinan T cell engagers aimed at BCMA and CD19, which drugmakers are exploring as possible targets for ...

Cabaletta announced promising results of its lead T-cell therapy candidate targeting autoimmune diseases. Eagles owner ...

Celiac disease frustratingly restrictive, the only real medical intervention for sufferers being to avoid gluten altogether.

Cullinan Therapeutics has announced a licensing agreement with Genrix Bio for global rights to velinotamig, a clinical-stage ...

The Cocoon® (from Lonza) is a functionally closed, sterile, efficient manufacturing platform, which combined with our ...

Capstan Therapeutics announces first participants dosed in its Phase 1 trial of lead in vivo CAR-T therapy, CPTX2309, for treating autoimmune disease.

Genrix’s velinotamig complements Cullinan’s own pipeline, according to William Blair, which added that the deal will put ...

It's been thought that T cells would only move into the brain in the case of a serious problem. New work shows otherwise... | Cell And Molecular Biology ...

A new study will evaluate the safety and efficacy of universal allogeneic anti-CD19/BCMA CAR T-cells in relapsed or refractory autoimmune diseases including antineutrophil cytoplasmic antibody ...

The dual-targeting CAR T-cell therapy KITE-363 showed positive response rates and manageable side effects in relapsed or ...